Phase I pharmacokinetic (PK) and pharmacodynamic (PD) study of PF-00337210, a highly selective VEGFR inhibitor
Liu G, LoRusso P, Goncalves P, Holen K, Traynor A, Zhang J, Hee B, Tortorici M, Shalinsky D, Ricart A. Phase I pharmacokinetic (PK) and pharmacodynamic (PD) study of PF-00337210, a highly selective VEGFR inhibitor. Journal Of Clinical Oncology 2009, 27: 3519-3519. DOI: 10.1200/jco.2009.27.15_suppl.3519.Peer-Reviewed Original ResearchAdverse eventsMyocardial ischemiaCommon treatment-related adverse eventsVEGFR inhibitorsTreatment-related adverse eventsVEGF/VEGFR inhibitorsAdvanced solid tumorsObserved accumulation ratioSelective VEGFR inhibitorsStable diseaseBID dosingChest painHypertensive effectSignificant hypertensionFirst doseObjective responseAntihypertensive agentsSafety profileDrug exposurePharmacodynamic studiesXenograft growthHypertensionVascular permeabilityPK dataVEGFR inhibition